YOUNG CONAWAY STARGATT & TAYLOR, LLP

BRUCE M. STARGATT BRUCE M. STARGATT BEN T. CASTLE SHELDON N. SANDLER RICHARD A. LEVINE RICHARD A. ZAPPA FREDERICK W. IOBST RICHARD H. MORSE DAVID C. MCBRIDE JOSEPH M. NICHOLSON CRAIG A. KARSNITZ BARRY M. WILLOUGHBY JOSY W. INGERSOLI ANTHONY G. FLYNN JEROME K. GROSSMAN EUGENE A. DIPRINZIO JAMES L. PATTON, JR. JAMES L. PATTON, JR.
ROBERT L. THOMAS
WILLIAM D. JOHNSTON
TIMOTHY J. SNYDER
BRUCE L. SILVERSTEIN
WILLIAM W. BOWSER WILLIAM W. BOWSER LARRY J. TARABICOS RICHARD A. DILIBERTO, JR. MELANIE K. SHARP CASSANDRA F. ROBERTS RICHARD J.A. POPPER TERESA A. CHEEK NEILLI MULLEN WALSH JANET Z. CHARLTON ROBERT S. BRADY JOEL A. WAITE BRENT C. SHAFFER DANIEL P. JOHNSON CRAIG D. GREAR TIMOTHY JAY HOUSEAL BRENDAN LINEHAN SHANNON MARTIN S. LESSNER PAULINE K. MORGAN C. BARR FLINN NATALIE WOLF LISA B. GOODMAN JOHN W. SHAW JAMES P. HUGHES, JR. FOWN I HARRON MICHAEL R. NESTOR

MAUREEN D. LUKE ROLIN P. BISSELL MATTHEW P. DENN SCOTT A. HOLT JOHN T. DORSEY

ATHANASIOS E. AGELAKOPOULOS JOSEPH M. BARRY KEVIN M. BAIRD SEAN M. BEACH TIMOTHY P. CAIRNS M. BLAKE CLEARY CURTIS J. CROWTHER ERIN EDWARDS IAN S. FREDERICKS (NJ & PA ONLY) DANIELLE GIBBS SEAN T. GREECHER KARA S. HAMMOND DAWN M. JONES RICHARD S. JULIE (NY ONLY) KAREN E. KELLER JENNIFER M. KINKUS EDWARD J. KOSMOWSKI JOHN C. KUFFEL (MD ONLY) TIMOTHY E. LENGKEEK MATTHEW B. LUNN JOSEPH A. MALFITANO GLENN C. MANDALAS ADRIA B. MARTINELLI MICHAEL W. MCDERMOTT MATTHEW B. MCGUIRE MARIBETH L. MINELLA EDMON I., MORTON JENNIFER R. NOEL JOHN I PASCHETTO ADAM W. POFF SETH J. REIDENBERG FRANCIS J. SCHANNE MICHAEL P. STAFFORD JOHN E. TRACEY ALFRED VILLOCH, III CHRISTIAN DOUGLAS WRIGHT

THE BRANDYWINE BUILDING 1000 WEST STREET, 17TH FLOOR WILMINGTON, DELAWARE 19801

P.O. Box 391 Wilmington, Delaware 19899-0391

> (302) 571-6600 (800) 253-2234 (DE ONLY) FAX: (302) 571-1253

WRITER'S DIRECT DIAL NUMBERS VOICE: (302) 571-6642 FAX: (302) 576-3326

E-MAIL: apoff@ycst.com

H. ALBERT YOUNG 1929-1982

H. JAMES CONAWAY, JR. 1947-1990

WILLIAM F. TAYLOR 1954-2004

STUART B. YOUNG EDWARD B. MAXWELL, 2ND SHELDON A. WEINSTEIN OF COUNSEL

JOHN D. MCLAUGHLIN, JR. ELENA C. NORMAN (NY ONLY) SPECIAL COUNSEL

GEORGETOWN OFFICE 110 WEST PINE STREET P.O. BOX 594 GEORGETOWN, DELAWARE 19947 (302) 856-3571 (800) 255-2234 (DE ONLY) FAX: (302) 856-9338

June 9, 2005

BY ELECTRONIC FILING

SHARON M. ZIEG

The Honorable Kent A. Jordan United States District Court 844 N. King Street Wilmington, DE 19801

Mayne Pharma (USA) Inc. v. American Pharmaceutical Partners, Inc., et al. U.S. Dist. Ct. C.A. No. 04-1564-KAJ

Dear Judge Jordan:

Re:

On behalf of plaintiff, Mayne Pharma (USA) Inc., we respectfully request that the Court schedule a Rule 16 conference to set a discovery schedule in this case. Counsel for defendant American Pharmaceutical Partners, Inc. ("APP") has ignored plaintiff's efforts to meet and confer concerning discovery pursuant to Rule 26(f), and has thereby prevented any discovery, based presumably on the ground that it has filed a partial motion to dismiss a small minority of the claims.

Discovery should be permitted to proceed, despite the pending motion, because substantially the same discovery will be needed from APP regardless of whether the partial motion to dismiss is granted. There is therefore no just reason for delay. To the contrary, plaintiff is incurring substantial irreparable competitive harm from not being able to supply certain drugs to the market, in competition with APP, as a result of the wrongful conduct challenged by the Complaint. Such harms will be exacerbated by any delay in obtaining a judgment.

WP3:1119502.1 ...

YOUNG CONAWAY STARGATT & TAYLOR, LLP

The Honorable Kent A. Jordan June 9, 2005 Page 2

The set of claims that is challenged by the pending motion and the set that is not so challenged address substantially the same facts, but with different legal theories. The facts concern APP's acquisition from defendants Bigmar Inc. and Bigmar-Bioren Pharmaceuticals, S.A. (together "Bigmar") of a manufacturing facility that Bigmar used to supply certain late-stage cancer drugs to plaintiff. The acquisition, together with APP's failure subsequently to honor Bigmar's supply contracts, precluded plaintiff from obtaining the drugs and therefore from competing with APP in the markets for these drugs. All claims against APP, regardless of whether they are a subject of the pending motion to dismiss, challenge the propriety of the acquisition and/or seek to hold APP liable for breach of the supply contracts.

The claims that *are not* subjects of the motion to dismiss challenge the acquisition as a violation of the federal antitrust laws, while the claims that *are* subjects of the motion challenge the transaction as a fraudulent conveyance. Similarly, the claims that *are not* subjects of the motion seek to hold APP liable for breach of the supply contracts on the ground that APP tortiously interfered with Bigmar's performance of the contracts, while the claims that *are* subjects of the motion seek to hold APP liable for breach of the contracts on the ground that APP was a successor to Bigmar under the contracts. Both sets of claims require discovery concerning the circumstances surrounding the acquisition, the supply contracts and APP's relationship to the contracts.

The motion to dismiss, even if granted, therefore should have little impact on the discovery needed in this case. There being no significant prejudice to APP from proceeding with discovery, and substantial prejudice to plaintiff from delaying it, APP should not be permitted to delay this proceeding by means of its motion to dismiss only a few of the claims that address substantially the same facts with different legal theories.

Respectfully submitted,

Adam W. Poff (#3990)

AWP

cc: Clerk of the Court

Thomas C. Grimm, Esquire

¹ Bigmar has defaulted in this proceeding and is now a subject of a request for entry of default.

WP3:1119502.1 ...